Big Pharma Deal Hunters Target RNA Approaches In Race To Build Best Platforms
Companies Search For Novel Modalities, Enabling Technology
The potential for RNA medicines to achieve holy grail goals – reaching undruggable targets and bringing drugs to market faster – has Pfizer, Lilly, Novartis and others in a deal-making frame of mind.
